Effects of Pamidronate on Dental Enamel Formation Assessed by Light Microscopy, Energy-Dispersive X-Ray Analysis, Scanning Electron Microscopy, and Microhardness Testing
Source abstract
Abstract
Abstract The aim of the present work was to investigate birefringence and morphology of the secretory-stage enamel organic extracellular matrix (EOECM), and structural and mechanical properties of mature enamel of upper incisors from adult rats that had been treated with pamidronate disodium (0.5 mg/kg/week for 56 days), using transmitted polarizing and bright-field light microscopies (TPLM and BFLM), energy-dispersive X-ray (EDX) analysis, scanning electron microscopy (SEM) and microhardness testing. BFLM showed no morphological changes of the EOECM in pamidronate and control groups, but TPLM revealed a statistically significant reduction in optical retardation values of birefringence brightness of pamidronate-treated rats when compared with control animals (p<0.01). EDX analysis showed that pamidronate-induced statistically significant decrease in phosphorus’ quantity in outer mature enamel (p<0.01) and an increase in the calcium/phosphorus ratio in that structure (p<0.05). Pamidronate did not induce ultra-structural alterations in mature enamel as revealed by SEM and did not cause a reduction in its microhardness (p>0.05). The present study indicates that pamidronate can affect birefringence of the secretory-stage EOECM, which does not seem to be associated with significant changes in morphological and/or mechanical properties of mature enamel.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Bone and Dental Protein Studies · Connective tissue disorders research · Bone health and treatments
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (46)
Show source-provided references
1. 10.1016/S0140-6736(13)61091-010.1016/S0140-6736(13)61091-0 ↗
2. 10.1369/jhc.5A6853.200610.1369/jhc.5A6853.2006 ↗
3. 10.1111/j.1469-8749.2008.03222.x10.1111/j.1469-8749.2008.03222.x ↗
4. 10.1097/bpo.0b013e3180316d0610.1097/bpo.0b013e3180316d06 ↗
5. Bisphosphonate therapy for osteogenesis imperfecta
6. 10.1177/0895937487001002270110.1177/08959374870010022701 ↗
7. 10.1136/bcr-2012-00853610.1136/bcr-2012-008536 ↗
8. 10.1210/jc.2010-063610.1210/jc.2010-0636 ↗
9. 10.1172/JCI11872210.1172/JCI118722 ↗
10. Dental enamel development: Proteinases and their enamel matrix substrates
11. 10.1056/NEJM19981001339140210.1056/NEJM199810013391402 ↗
12. Prospective use of bisphosphonates in osteoporosis
13. 10.1177/0895937489003002240110.1177/08959374890030022401 ↗
14. 10.1111/j.1651-2227.2003.tb00577.x10.1111/j.1651-2227.2003.tb00577.x ↗
15. Summary of the IADR Cariology Research, Craniofacial Biology, and Mineralized Tissue Groups Symposium, Iguaçu Falls, Brazil, June 2012: Gene-environment interactions and epigenetics in oral diseases: enamel formation and its clinical impact on tooth defects, caries, and erosion
16. 10.2330/joralbiosci1965.33.8210.2330/joralbiosci1965.33.82 ↗
17. 10.1016/S0003-9969(00)00009-110.1016/S0003-9969(00)00009-1 ↗
18. 10.1002/ar.109225031210.1002/ar.1092250312 ↗
19. 10.1002/pbc.2268110.1002/pbc.22681 ↗
20. 10.1080/0300820060105917510.1080/03008200601059175 ↗
21. 10.1016/j.bone.2011.04.02210.1016/j.bone.2011.04.022 ↗
22. 10.1016/j.bjoms.2012.05.00810.1016/j.bjoms.2012.05.008 ↗
23. 10.1210/jc.2008-153110.1210/jc.2008-1531 ↗
24. 10.1055/s-2007-97900810.1055/s-2007-979008 ↗
25. 10.3109/0300820090328011510.3109/03008200903280115 ↗
26. The effect of a single dose of 1-hydroxyethylidene-1, 1-bisphosphonate (HEBP) on secretory ameloblasts and enamel formation in rat incisors
27. 10.1111/j.1600-0722.2008.00529.x10.1111/j.1600-0722.2008.00529.x ↗
28. 10.1007/s00774-011-0262-z10.1007/s00774-011-0262-z ↗
29. 10.1111/j.1600-0722.2006.00326.x10.1111/j.1600-0722.2006.00326.x ↗
30. 10.1007/BF0029665810.1007/BF00296658 ↗
31. 10.1515/jpem-2012-001610.1515/jpem-2012-0016 ↗
32. 10.1016/j.bone.2011.01.01410.1016/j.bone.2011.01.014 ↗
33. 10.1007/s00223-010-9366-z10.1007/s00223-010-9366-z ↗
34. 10.1016/S0003-9969(99)00134-X10.1016/S0003-9969(99)00134-X ↗
35. 10.1159/00036588910.1159/000365889 ↗
36. Mineralization disturbances of the developing rat molar induced by mono- and bisphosphonates
37. 10.1007/s11832-012-0383-510.1007/s11832-012-0383-5 ↗
38. 10.1002/jemt.2205910.1002/jemt.22059 ↗
39. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive pontencies in vitro and in vivo
40. 10.1097/00001813-200203000-0000610.1097/00001813-200203000-00006 ↗
41. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age
42. 10.3109/0300820950901370010.3109/03008209509013700 ↗
43. 10.1016/0003-9969(90)90064-H10.1016/0003-9969(90)90064-H ↗
44. Bisphosphonate therapy for osteogenesis imperfecta
45. The effect of a single dose of 1-hydroxyethylidene-1,1-bisphosphonate (HEBP) on presecretory ameloblast differentiation in rat incisors
46. 10.1016/S8756-3282(01)00655-X10.1016/S8756-3282(01)00655-X ↗